智通财经APP获悉，艾美疫苗(06660)盘中涨超6%，截至发稿，涨4.71%，报4港元，成交额809.17万港元。
消息面上，5月19日，艾美疫苗公告，公司研发的mRNA带状疱疹疫苗，继2025年3月获美国FDA批准开展临床试验后，又于近日获得国家药品监督管理局《药物临床试验批准通知书》，中美双报均获批准。临床前试验数据显示，艾美疫苗的mRNA带状疱疹疫苗在关键免疫指标上展现出显著优势。
复星国际证券此前发布研报称，艾美疫苗已成功商业化8款疫苗，包括市场领先的狂犬病疫苗和乙肝疫苗，销售网络覆盖全国并已拓展至海外。更重要的是，公司拥有涵盖21款在研疫苗的丰富管线，覆盖五大技术平台，2025-2028年预计将有10+款重磅产品上市销售，其中三大单品：PCV13、迭代无血清狂犬、PPSV23已进入上市冲刺阶段，未来1-2年将陆续上市，驱动公司业绩实现跨越式增长和价值重估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.